Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06187012

Hypertension Explored in Long-term Postpartum Follow-up in Later Life

Hypertension Explored in Long-term Postpartum Follow-up in Later Life — Recruiting • Cardiology / Cardiovascular • NCT06187012.

📅 29 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06187012
Sponsor
University of Oxford
Start
2023-03-23
ClinicaliQ Trial Snapshot
  • Hypertension Explored in Long-term Postpartum Follow-up in Later Life — Recruiting • Cardiology / Cardiovascular • NCT06187012.
  • What is being tested: The study investigates the long-term cardiovascular mechanisms linking hypertensive pregnancy disorders (gestational hypertension and preeclampsia) to increased risk of chronic hypertension and cardiovascular disease in postpartum women followed into later life.
  • Patient eligibility overview: The trial enrolls women with prior hypertensive pregnancies (gestational hypertension or preeclampsia) for extended postpartum follow-up assessment, comparing their cardiovascular profiles to women with normotensive pregnancies.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this study is to understand more about why women who have had hypertensive pregnancies may be at increased risk of high blood pressure and why these women are often at increased risk of heart and blood vessel disease later in life.

Eligibility Snapshot
  • : * Inclusion Criteria * Participant is willing and able to give informed consent for participation in the study * Female who had a pregnancy 10 to 25 years prior * Able (in the investigator's opinion) and willing to comply with all study requirements. * Adequate understanding of verbal and written English

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Cardiology / Cardiovascular · 27 Mar 2026
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year…
View guideline →
Guideline
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Insert a catheter-based left ventricular microaxial flow pump in patients with acute cardiogenic shock refractory to medical therapy and inotropic support, as…
View guideline →
Guideline
Aortic Valve Disease: TAVI and Surgical Replacement (NICE TA631)
Cardiology / Cardiovascular · 27 Mar 2026
Offer TAVI as first-line intervention for symptomatic aortic stenosis in patients at high or prohibitive surgical risk, or with severe comorbidities precluding…
View guideline →
Clinical Brief
Mesalazine and idiopathic intracranial hypertension
Cardiology / Cardiovascular · MHRA · 04 Dec 2025
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are…
View brief →